Delgado, R.; Kielbassa, K.; ter Burg, J.; Klein, C.; Trumpfheller, C.; de Heer, K.; Kater, A.P.; Eldering, E.
Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia. Cancers 2021, 13, 3084.
https://doi.org/10.3390/cancers13123084
AMA Style
Delgado R, Kielbassa K, ter Burg J, Klein C, Trumpfheller C, de Heer K, Kater AP, Eldering E.
Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia. Cancers. 2021; 13(12):3084.
https://doi.org/10.3390/cancers13123084
Chicago/Turabian Style
Delgado, Raquel, Karoline Kielbassa, Johanna ter Burg, Christian Klein, Christine Trumpfheller, Koen de Heer, Arnon P. Kater, and Eric Eldering.
2021. "Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia" Cancers 13, no. 12: 3084.
https://doi.org/10.3390/cancers13123084
APA Style
Delgado, R., Kielbassa, K., ter Burg, J., Klein, C., Trumpfheller, C., de Heer, K., Kater, A. P., & Eldering, E.
(2021). Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia. Cancers, 13(12), 3084.
https://doi.org/10.3390/cancers13123084